Apogee Eczema Data Sends Stock Up 20%; Gilead Nears $2B Ouro Medicines Deal

Apogee's zumilokibart shows every-3-to-6-month dosing in atopic dermatitis, stock surges 20%+. Gilead nears $2B Ouro Medicines acquisition. Insmed Arikayce ENCORE Phase 3b hits primary endpoint in MAC lung disease. Dizal Zegfrovy pressures J&J's Rybrevant with first-line NSCLC data. Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Apogee Therapeutics, zumilokibart, atopic dermatitis, eczema, Dupixent, Gilead, Ouro Medicines, Insmed, Arikayce, MAC lung disease, Dizal, Zegfrovy, sunvozertinib, Rybrevant, Sanofi, Kali Therapeutics, T cell engager, Aurinia, Kevin Tang, M&A, Lilly, Novartis, AstraZeneca, J&J, Regeneron